{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=6", "query": { "intervention": "Protein Control", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 3497, "total_pages": 350, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T22:27:42.101Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01445899", "title": "PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Choroidal Neovascularization", "Diabetic Retinopathy", "Diabetic Macular Edema" ], "interventions": [ { "name": "PF-04523655 (Stratum I)", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "PF-04523655 (Stratum II)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Quark Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2012-02", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2015-02-23", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445899" }, { "nct_id": "NCT00858364", "title": "Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer", "Anemia", "Cancer", "Lung Cancer" ], "interventions": [ { "name": "Darbepoetin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2549, "start_date": "2009-07-17", "completion_date": "2017-06-07", "has_results": true, "last_update_posted_date": "2022-11-30", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 277, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858364" }, { "nct_id": "NCT00663169", "title": "Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Gouty" ], "interventions": [ { "name": "canakinumab", "type": "BIOLOGICAL" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "placebo matching canakinumab", "type": "OTHER" }, { "name": "placebo matching dexamethasone", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 6, "start_date": "2008-04", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 2, "location_summary": "Birmingham, Alabama • New Brunswick, New Jersey", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00663169" }, { "nct_id": "NCT02174783", "title": "Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Liver Transplantation", "Metabolic Syndrome X", "Obesity" ], "interventions": [ { "name": "Control group", "type": "OTHER" }, { "name": "Mediterranean diet", "type": "OTHER" }, { "name": "Protein-Sparing Modified Fast (PSMF)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-06", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02174783" }, { "nct_id": "NCT04294472", "title": "A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BK Virus Infection" ], "interventions": [ { "name": "MAU868", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vera Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-08-05", "completion_date": "2022-02-10", "has_results": true, "last_update_posted_date": "2023-06-07", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04294472" }, { "nct_id": "NCT00642356", "title": "Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Carbidopa/levodopa/entacapone", "type": "DRUG" }, { "name": "Immediate release carbidopa/levodopa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 14, "start_date": "2008-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2011-02-18", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Aliso Viejo, California • Irvine, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aliso Viejo", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642356" }, { "nct_id": "NCT06580145", "title": "Leucine in Midlife Depression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depression" ], "interventions": [ { "name": "L-leucine", "type": "DRUG" }, { "name": "L-lysine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "35 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2025-02-01", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06580145" }, { "nct_id": "NCT07225998", "title": "Oral N-acetylglucosamine in Crohn's Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohns Disease" ], "interventions": [ { "name": "N-Acetylglucosamine (GlcNAc)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 40, "start_date": "2026-11-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07225998" }, { "nct_id": "NCT05013229", "title": "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "IcoSema", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 679, "start_date": "2021-11-30", "completion_date": "2023-11-14", "has_results": false, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 66, "location_summary": "Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more", "locations": [ { "city": "Guntersville", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013229" }, { "nct_id": "NCT01682031", "title": "Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapeutic Agent Toxicity", "Mucositis", "Radiation Toxicity", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Xerostomia" ], "interventions": [ { "name": "selenomethionine", "type": "DIETARY_SUPPLEMENT" }, { "name": "placebo", "type": "OTHER" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2009-06", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2014-08-22", "last_synced_at": "2026-10-22T22:27:42.101Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01682031" } ] }